Barclays PLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 162.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 207,309 shares of the company's stock after acquiring an additional 128,246 shares during the quarter. Barclays PLC owned about 0.20% of Dyne Therapeutics worth $7,446,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of DYN. SG Americas Securities LLC purchased a new stake in Dyne Therapeutics in the second quarter valued at $217,000. Nisa Investment Advisors LLC raised its holdings in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after buying an additional 669 shares during the period. Bank of New York Mellon Corp lifted its position in Dyne Therapeutics by 52.5% in the second quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company's stock valued at $10,993,000 after buying an additional 107,233 shares during the last quarter. Legato Capital Management LLC boosted its stake in Dyne Therapeutics by 35.3% during the second quarter. Legato Capital Management LLC now owns 15,480 shares of the company's stock worth $546,000 after buying an additional 4,035 shares during the period. Finally, Lisanti Capital Growth LLC increased its position in shares of Dyne Therapeutics by 22.5% during the second quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company's stock valued at $3,746,000 after acquiring an additional 19,530 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.
DYN has been the subject of a number of research analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Oppenheimer reaffirmed an "outperform" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. lowered Dyne Therapeutics from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Royal Bank of Canada assumed coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an "outperform" rating and a $45.00 target price for the company. Finally, Chardan Capital reissued a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.42.
Read Our Latest Stock Report on DYN
Shares of NASDAQ:DYN opened at $24.56 on Thursday. The firm has a 50 day simple moving average of $29.99 and a 200-day simple moving average of $35.11. The company has a market capitalization of $2.50 billion, a PE ratio of -6.90 and a beta of 1.09. Dyne Therapeutics, Inc. has a twelve month low of $11.66 and a twelve month high of $47.45.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.
In related news, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. This represents a 1.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 167,341 shares of company stock worth $5,862,564 in the last quarter. 20.77% of the stock is owned by insiders.
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.